Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51 - PubMed (original) (raw)

Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51

M Novak et al. Proc Natl Acad Sci U S A. 1991.

Abstract

The microtubule-associated protein tau that is incorporated into paired helical filaments (PHFs) undergoes some form of aberrant posttranslational processing in Alzheimer disease. Difficulties in deciding which changes are critical for PHF formation stem in part from the lack of immunochemical markers specific for PHF tau. The only monoclonal antibody (mAb) that is known to react with PHF tau but not with the predominant normal adult tau species is mAb 423. Another mAb (7.51, described in this paper) recognizes a segment of tau that is included in the minimal recognition unit required by mAb 423. Unlike 423, which is PHF tau-specific, mAb 7.51 recognizes all PHF core-derived tau as well as native soluble tau and recombinant tau expressed in bacteria and so serves as a generic tau marker. Both epitopes are in the 12-kDa fragment released from the Pronase-resistant core of the PHF (which encompasses the tandem repeat region). The mAb 7.51 epitope requires segments located in the last two repeats, which are common to all tau isoforms. The mAb 423 epitope requires sequences located near both the N and the C terminus of the 12-kDa fragment common to three- and four-repeat tau isoforms. Fragments denatured by concentrated formic acid and SDS regain 423 reactivity when denaturing agents are removed. Since the primary amino acid sequences of PHF tau and normal tau are identical in the repeat region, we conclude that 423 reactivity also requires a modification(s) occurring within an approximately 90-residue segment that are not present in tau proteins so far described in the human brain.

PubMed Disclaimer

Cited by

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease.
Lai RY, Harrington CR, Wischik CM. Lai RY, et al. Biomolecules. 2016 Apr 8;6(2):19. doi: 10.3390/biom6020019. Biomolecules. 2016. PMID: 27070645 Free PMC article.
Tau as a Biomarker of Neurodegeneration.
Holper S, Watson R, Yassi N. Holper S, et al. Int J Mol Sci. 2022 Jun 30;23(13):7307. doi: 10.3390/ijms23137307. Int J Mol Sci. 2022. PMID: 35806324 Free PMC article. Review.
Biochemical and anatomical redistribution of tau protein in Alzheimer's disease.
Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM. Mukaetova-Ladinska EB, et al. Am J Pathol. 1993 Aug;143(2):565-78. Am J Pathol. 1993. PMID: 8342603 Free PMC article.
A Simple Model to Study Tau Pathology.
Houck AL, Hernández F, Ávila J. Houck AL, et al. J Exp Neurosci. 2016 Feb 25;10:31-8. doi: 10.4137/JEN.S25100. eCollection 2016. J Exp Neurosci. 2016. PMID: 26949341 Free PMC article.
Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.
Harrington CR, Storey JM, Clunas S, Harrington KA, Horsley D, Ishaq A, Kemp SJ, Larch CP, Marshall C, Nicoll SL, Rickard JE, Simpson M, Sinclair JP, Storey LJ, Wischik CM. Harrington CR, et al. J Biol Chem. 2015 Apr 24;290(17):10862-75. doi: 10.1074/jbc.M114.616029. Epub 2015 Mar 10. J Biol Chem. 2015. PMID: 25759392 Free PMC article.

References

1. J Biol Chem. 1987 Jul 25;262(21):10035-8 - PubMed
1. Folia Biol (Praha). 1988;34(1):18-22 - PubMed
1. Am J Pathol. 1990 Sep;137(3):497-502 - PubMed
1. Acta Neuropathol. 1990;80(2):212-5 - PubMed
1. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5827-31 - PubMed

Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51 - PubMed (original) (raw)